LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM MITIGATES INFLAMMATION AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS

被引：0
|
作者：
Wang, X. -Y. [1 ]
Weng, S. -Y. [1 ]
Kim, Y. O. [1 ]
Klein, T. [2 ]
Schuppan, D. [1 ,3 ]
机构：
[1] Inst Translat Immunol, Mainz, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)60791-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [31] Pharmacological Evaluation of SKL-18287, a New Long-Acting Glucagon-Like Peptide-1 Receptor Agonist with Enhanced Aggregation Propensity, in Rodent Models
    Mitsuaki Takeuchi
    Masayuki Okamoto
    Nobuhide Watanabe
    International Journal of Peptide Research and Therapeutics, 2019, 25 : 1309 - 1317
  • [32] Pharmacological Evaluation of SKL-18287, a New Long-Acting Glucagon-Like Peptide-1 Receptor Agonist with Enhanced Aggregation Propensity, in Rodent Models
    Takeuchi, Mitsuaki
    Okamoto, Masayuki
    Watanabe, Nobuhide
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2019, 25 (04) : 1309 - 1317
  • [33] Glucagon-like peptide-1, fused to human transferrin, is a long-acting and potent anti-hyperglycemic agent
    Egan, JM
    Zhou, J
    Carlson, OD
    Kim, BJ
    Wustner, J
    Sadeghi, H
    DIABETOLOGIA, 2005, 48 : A202 - A202
  • [34] Glucagon-Like Peptide-1 Receptor Agonism and Suicide Risk: Evidence From Mendelian Randomization
    Zhao, Sizheng Steven
    Burgess, Stephen
    Gill, Dipender
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (12):
  • [35] Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
    Bush, M. A.
    Matthews, J. E.
    De Boever, E. H.
    Dobbins, R. L.
    Hodge, R. J.
    Walker, S. E.
    Holland, M. C.
    Gutierrez, M.
    Stewart, M. W.
    DIABETES OBESITY & METABOLISM, 2009, 11 (05): : 498 - 505
  • [36] Design, synthesis, and biological evaluation of a potential long-acting glucagon-like peptide-1 (GLP-1) analog
    Zhang, Jinhua
    Xu, Hongjiang
    Lu, Jianguang
    Dong, Yuanzhen
    Feng, Jun
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 85
  • [37] Glucagon-like peptide-1 receptor agonists ameliorate inflammation and fibrosis in an optimized rodentNASH model via inhibition of inflammatory macrophage activation
    Wang, X.
    Weng, S. -Y.
    Chen, T.
    Molokanova, O.
    Schattenberg, J.
    Klein, T.
    Schuppan, D.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S610 - S611
  • [38] Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds
    Zhou, Yan
    Li, Jianhui
    Gao, Guosheng
    Li, Yafeng
    Zhang, Changzhen
    HELIYON, 2024, 10 (02)
  • [39] Equine glucagon-like peptide-1 receptor physiology
    Kheder, Murad H.
    Bailey, Simon R.
    Dudley, Kevin J.
    Sillence, Martin N.
    de Laat, Melody A.
    PEERJ, 2018, 6
  • [40] Glucagon-like peptide-1 receptor action in the vasculature
    Almutairi, Malak
    Al Batran, Rami
    Ussher, John R.
    PEPTIDES, 2019, 111 : 26 - 32
12345